Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...

Longer-term follow-up from the Phase 1b/2 OrigAMI-1 study shows that amivantamab (Rybrevant) plus FOLFOX or FOLFIRI achieved ...

Novartis announced plans to build a fourth US radioligand therapy manufacturing facility in Winter Park, Florida, as part of ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical for advanced hepatocellular carcinoma. The therapy uses a GPC3-targeting ...

Roche has announced that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Elecsys pTau217 blood test for the diagnosis of Alzheimer’s disease. This ...

Rznomics has received FDA Orphan Drug Designation for RZ-001, a novel RNA-based therapy for Hepatocellular carcinoma. RZ-001 employs advanced RNA editing to target and suppress cancer growth, showing ...

An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...

Researchers at Mass General Brigham engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five immunomodulators, and avoids healthy brain tissue. A single ...

Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, marking another major step in its $23 billion U.S. expansion plan. The site, the ...

The FDA has granted Breakthrough Device Designation to PreveCol, a blood test for early colorectal cancer detection developed by Amadix. PreveCol excels in identifying precancerous lesions more ...

Everest Medicines' licensing partner Calliditas Therapeutics announced that the FDA approved Nefecon to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at ...